These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 20809175

  • 21. Invasive carcinoma derived from intraductal papillary mucinous carcinoma of the pancreas.
    Nakagohri T, Konishi M, Inoue K, Tanizawa Y, Kinoshita T.
    Hepatogastroenterology; 2004; 51(59):1480-3. PubMed ID: 15362782
    [Abstract] [Full Text] [Related]

  • 22. Parenchyma-sparing pancreatectomy for presumed noninvasive intraductal papillary mucinous neoplasms of the pancreas.
    Sauvanet A, Gaujoux S, Blanc B, Couvelard A, Dokmak S, Vullierme MP, Ruszniewski P, Belghiti J, Lévy P.
    Ann Surg; 2014 Aug; 260(2):364-71. PubMed ID: 24646561
    [Abstract] [Full Text] [Related]

  • 23. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.
    Sohn TA, Yeo CJ, Cameron JL, Hruban RH, Fukushima N, Campbell KA, Lillemoe KD.
    Ann Surg; 2004 Jun; 239(6):788-97; discussion 797-9. PubMed ID: 15166958
    [Abstract] [Full Text] [Related]

  • 24. Prognosis of invasive intraductal papillary mucinous neoplasm.
    Longnecker DS, Klöppel G.
    Pancreas; 2008 Oct; 37(3):333; author reply 333-4. PubMed ID: 18815559
    [No Abstract] [Full Text] [Related]

  • 25. Invasive carcinoma derived from intestinal-type intraductal papillary mucinous neoplasm is associated with minimal invasion, colloid carcinoma, and less invasive behavior, leading to a better prognosis.
    Nakata K, Ohuchida K, Aishima S, Sadakari Y, Kayashima T, Miyasaka Y, Nagai E, Mizumoto K, Tanaka M, Tsuneyoshi M, Oda Y.
    Pancreas; 2011 May; 40(4):581-7. PubMed ID: 21499213
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology.
    Schmidt CM, White PB, Waters JA, Yiannoutsos CT, Cummings OW, Baker M, Howard TJ, Zyromski NJ, Nakeeb A, DeWitt JM, Akisik FM, Sherman S, Pitt HA, Lillemoe KD.
    Ann Surg; 2007 Oct; 246(4):644-51; discussion 651-4. PubMed ID: 17893501
    [Abstract] [Full Text] [Related]

  • 29. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades.
    Winter JM, Brennan MF, Tang LH, D'Angelica MI, Dematteo RP, Fong Y, Klimstra DS, Jarnagin WR, Allen PJ.
    Ann Surg Oncol; 2012 Jan; 19(1):169-75. PubMed ID: 21761104
    [Abstract] [Full Text] [Related]

  • 30. Intraductal papillary mucinous neoplasms of the pancreas: clinicopathological features and long term outcome related to histopathological group.
    De Moor V, Arvanitakis M, Nagy N, Coppens E, Delhaye M, Closset J.
    Hepatogastroenterology; 2012 Jan; 59(114):565-9. PubMed ID: 22353525
    [Abstract] [Full Text] [Related]

  • 31. Characterization of CD24 expression in intraductal papillary mucinous neoplasms and ductal carcinoma of the pancreas.
    Ikenaga N, Ohuchida K, Mizumoto K, Yu J, Kayashima T, Hayashi A, Nakata K, Tanaka M.
    Hum Pathol; 2010 Oct; 41(10):1466-74. PubMed ID: 20619441
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Outcome after surgical resection of intraductal papillary and mucinous tumors of the pancreas.
    Cuillerier E, Cellier C, Palazzo L, Devière J, Wind P, Rickaert F, Cugnenc PH, Cremer M, Barbier JP.
    Am J Gastroenterol; 2000 Feb; 95(2):441-5. PubMed ID: 10685747
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Surgical aspects of intraductal papillary mucinous neoplasm of the pancreas].
    Oláh A.
    Magy Seb; 2014 Apr; 67(2):39-43. PubMed ID: 24747402
    [Abstract] [Full Text] [Related]

  • 36. Nonoperative management of main pancreatic duct-involved intraductal papillary mucinous neoplasm might be indicated in select patients.
    Roch AM, DeWitt JM, Al-Haddad MA, Schmidt CM, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, Schmidt CM.
    J Am Coll Surg; 2014 Jul; 219(1):122-9. PubMed ID: 24862887
    [Abstract] [Full Text] [Related]

  • 37. Malignant progression in IPMN: a cohort analysis of patients initially selected for resection or observation.
    Lafemina J, Katabi N, Klimstra D, Correa-Gallego C, Gaujoux S, Kingham TP, Dematteo RP, Fong Y, D'Angelica MI, Jarnagin WR, Do RK, Brennan MF, Allen PJ.
    Ann Surg Oncol; 2013 Feb; 20(2):440-7. PubMed ID: 23111706
    [Abstract] [Full Text] [Related]

  • 38. [Differentiated therapy for intraductal papillary mucinous neoplasms].
    Wente MN, Schmied BM, Schmidt J, Büchler MW.
    Chirurg; 2009 Jan; 80(1):7-13. PubMed ID: 19082569
    [Abstract] [Full Text] [Related]

  • 39. Malignant intraductal papillary mucinous neoplasm: are we doing the right thing?
    Simons JP, Ng SC, Shah SA, McDade TP, Whalen GF, Tseng JF.
    J Surg Res; 2011 May 15; 167(2):251-7. PubMed ID: 19765732
    [Abstract] [Full Text] [Related]

  • 40. Intraductal papillary-mucinous neoplasms of the gastric and intestinal types may have less malignant potential than the pancreatobiliary type.
    Takasu N, Kimura W, Moriya T, Hirai I, Takeshita A, Kamio Y, Nomura T.
    Pancreas; 2010 Jul 15; 39(5):604-10. PubMed ID: 20124938
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.